BrainChild Bio raises $116M Series A from Seattle Children’s and WRF to fund pivotal CAR-T trial for DIPG

BrainChild Bio, spun out of Seattle Children’s Hospital, raised $116 million in a Series A led by Seattle Children’s and WRF Capital to fund a pivotal phase 2 trial of CAR-T candidate BCB-276 for diffuse intrinsic pontine glioma (DIPG) and advance a planned phase 1 glioblastoma program.

SSteven Brugger MMichael Jensen BBrainChild Bio WWashington Research Foundation SSeattle Children's Hospital